Persistence of SARS‐CoV‐2 antibodies in kidney transplant recipients

Data on the long‐ and middle‐term dynamics of antibody response to SARS‐CoV‐2 after COVID‐19 in the immunocompromised population remain scanty, while reports on a decrease in antibody titers in immunocompetent patients are controversial.1,2 We have previously described the serological response again...

Full description

Saved in:
Bibliographic Details
Published inAmerican Journal of Transplantation Vol. 21; no. 6; pp. 2307 - 2310
Main Authors Benotmane, Ilies, Gautier Vargas, Gabriela, Velay, Aurélie, Wendling, Marie‐José, Perrin, Peggy, Fafi‐Kremer, Samira, Caillard, Sophie
Format Journal Article Web Resource
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.06.2021
Elsevier Limited
Subjects
antibody biology
biomarker
clinical research/practice
COVID-19
Humans
immune deficiency
Immunosuppressive Agents
infection and infectious agents – viral
infectious disease
Kidney Transplantation
kidney transplantation/nephrology
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Transplant Recipients
antibody biology
immune deficiency
infectious disease
clinical research/practice
kidney transplantation/nephrology
biomarker
infection and infectious agents - viral
Online AccessGet full text

Cover

More Information
Summary:Data on the long‐ and middle‐term dynamics of antibody response to SARS‐CoV‐2 after COVID‐19 in the immunocompromised population remain scanty, while reports on a decrease in antibody titers in immunocompetent patients are controversial.1,2 We have previously described the serological response against SARS‐CoV‐2 in 35 kidney transplant recipients (KTR) hospitalized for COVID‐19 until two months after symptoms onset.
Bibliography:Sophie Caillard and Samira Fafi‐Kremer contributed equally to this work.
SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.16469